株式会社ジーエヌアイグループ 2025年12月期 第１四半期 決算説明資料

This document is the financial results presentation for the first quarter of the fiscal year ending December 2025 for GNI Group Ltd. It includes an overview of the company, highlights of the financial results, segment-wise performance, and forecasts for the current fiscal year. Key points include changes in revenue and operating profit, an increase in research and development expenses, and growth in the medtech sector. It also discusses the development status of the leading product, ETUARY® (pirfenidone), for idiopathic pulmonary fibrosis, and the candidate drug F351 for liver fibrosis. Overall, it outlines the company's strategies and performance in the global pharmaceutical market.